Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
INBRX-106 by Inhibrx Biosciences for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
INBRX-106 is under clinical development by Inhibrx Biosciences and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...